Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

249

Citations

34

References

2012

Year

Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, Martin J. Edelman, Miguel A. Villalona‐Calero, Robert A. Kratzke,

Journal of Clinical Oncology

Abstract

Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. EGFR mutations identify patients most likely to benefit.

References

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Cancer Statistics, 2010 Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu, CA A Cancer Journal for Clinicians	2010	12.6K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Science	2004	9.4K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Alan Sandler, Robert J. Gray, Michael C. Perry, New England Journal of Medicine	2006	5.8K
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, New England Journal of Medicine	2010	5.5K
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, New England Journal of Medicine	2005	5.4K
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David Harrington, Chandra P. Belani, New England Journal of Medicine	2002	4.9K

Page 1